Letter from the Editor: Ensuring appropriate diversity in clinical trials

被引：0
|
作者：
Elston, Dirk M. [1 ]
机构：
[1] Med Univ South Carolina, Dept Dermatol & Dermatol Surg, MSC 578,135 Rutledge Ave,11th Floor, Charleston, SC 29425 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2024年 / 91卷 / 06期
关键词：
clinical trials; diverse populations; diversity; meeting the challenge summit; nomenclature; skin of color patient safety;
D O I：
10.1016/j.jaad.2023.12.024
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：1069 / 1070
页数：2
相关论文
共 50 条
  • [31] A RESPONSE TO THE LETTER TO THE EDITOR FROM ORTEGA BELTRAN AND BANDYOPADHYAY
    Molo, Megan S.
    Carbone, Ignazio
    Heiniger, Ron W.
    Boerema, Leah
    AGRONOMY JOURNAL, 2019, 111 (05) : 2629 - 2631
  • [32] Quantifying Clinical Trial Diversity in Pivotal Registration Trials of FDA Novel Drug Approvals
    Muhammed Y. Idris
    William E. Fitzsimmons
    Priscilla Pemu
    Therapeutic Innovation & Regulatory Science, 2024, 58 : 175 - 183
  • [33] Building trust and diversity in patient-centered oncology clinical trials: An integrated model
    Hurd, Thelma C.
    Kaplan, Charles D.
    Cook, Elise D.
    Chilton, Janice A.
    Lytton, Jay S.
    Hawk, Ernest T.
    Jones, Lovell A.
    CLINICAL TRIALS, 2017, 14 (02) : 170 - 179
  • [34] Quantifying Clinical Trial Diversity in Pivotal Registration Trials of FDA Novel Drug Approvals
    Idris, Muhammed Y.
    Fitzsimmons, William E.
    Pemu, Priscilla
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (01) : 175 - 183
  • [35] Ethics in musculoskeletal regenerative medicine; guidance in choosing the appropriate comparator in clinical trials
    de Windt, T. S.
    Niemansburg, S. L.
    Vonk, L. A.
    van Delden, J. M.
    Roes, K. C. B.
    Dhert, W. J. A.
    Saris, D. B. F.
    Bredenoord, A. L.
    OSTEOARTHRITIS AND CARTILAGE, 2019, 27 (01) : 34 - 40
  • [36] Which geriatric assessment approach is appropriate in multi-centre clinical trials?
    Chaladaj, A.
    Terret, C.
    Albrand, G.
    Courpron, P.
    Droz, J. -P.
    ONCOLOGIE, 2007, 9 (03) : 186 - 191
  • [37] Confronting diversity in the production of clinical evidence goes beyond merely including under-represented groups in clinical trials
    Stronks, Karien
    Wieringa, Nicolien F.
    Hardon, Anita
    TRIALS, 2013, 14
  • [38] Confronting diversity in the production of clinical evidence goes beyond merely including under-represented groups in clinical trials
    Karien Stronks
    Nicolien F Wieringa
    Anita Hardon
    Trials, 14
  • [39] Diversity of US participants in AstraZeneca-sponsored clinical trials
    Cabrera, Claudia
    Fernandez-Llaneza, Daniel
    Ghazoui, Zara
    D'Abrantes, Sofia
    Esparza-Franco, M. Alejandro
    Sopp, Charles
    Maj, Beata
    Chiou, Victoria L.
    Valastro, Barbara
    Pangalos, Menelas N.
    Galbraith, Susan
    Ghiorghiu, Serban
    Massacesi, Cristian
    CONTEMPORARY CLINICAL TRIALS, 2024, 140
  • [40] Racial/Ethnic Diversity in Children's Oncology Clinical Trials
    Lund, Mary Jo
    Eliason, Mark T.
    Haight, Ann E.
    Ward, Kevin C.
    Young, John L.
    Pentz, Rebecca D.
    CANCER, 2009, 115 (16) : 3808 - 3816
12345